Do vaginal lasers or radiofrequency help GSM?
Vaginal lasers and radiofrequency (RF) aim to warm tissues and stimulate repair for genitourinary syndrome of menopause (GSM), sometimes easing dryness or dyspareunia. Evidence is mixed and quality varies; guideline-led first lines remain moisturisers, suitable lubricants and, when needed, local vaginal oestrogen or DHEA. Energy devices are usually considered only after these. Educational only. Results vary. Not a cure.
Detailed Medical Explanation
Do vaginal lasers or radiofrequency help GSM? Energy-based treatments (fractional CO2 or Er:YAG lasers; monopolar or bipolar RF) deliver controlled heat to the vaginal epithelium and submucosa. The goal is to prompt a wound-heal/remodel response—more collagen and elastic fibres, improved blood flow—which may reduce friction, dryness and insertional pain (dyspareunia) in some people with genitourinary syndrome of menopause (GSM). Reports often describe reduced “sandpaper” discomfort on walking or cycling, fewer micro-tears at the entrance (vestibule/posterior fourchette), and better arousal comfort over weeks to months.
Where these fit in a UK, guideline-led pathway. By UK guidance, first try non-hormonal foundations: a scheduled vaginal moisturiser (many prefer hyaluronic acid gels) several times weekly for day-to-day hydration, plus a compatible personal lubricant for higher-friction moments—water-based (versatile, condom-friendly), silicone-based (long-lasting glide for vestibular tenderness) or oil-based (rich feel but may degrade latex condoms and some toys). If dryness or urinary urgency/frequency persists, local vaginal oestrogen (cream, tablet/pessary, ring) or vaginal DHEA addresses the low-oestrogen biology more directly for many. Energy devices are generally considered after these steps, or when hormones are unsuitable/declined and symptoms remain intrusive despite good foundations.
What improvement feels like—and what it doesn’t do. When energy-based care helps, people usually notice easier glide with less sting on initial penetration, fewer superficial fissures and calmer day-to-day movement. It does not treat infections (thrush/BV/UTIs) and does not replace pelvic floor physiotherapy when protective muscle over-activity is keeping the entrance tight. If burning remains focused at the vestibule, placement of any local therapy (for example, fingertip-applied cream at the entrance) can matter as much as the device choice.
Safety, regulation and device choice. UK devices should be UKCA/CE-marked for their intended use, operated by trained clinicians with clear consent and aftercare. Common, usually mild effects include transient warmth, spotting or soreness; short downtime is typical. Red flags (fever, malodorous discharge, heavy bleeding, severe pelvic pain, visible blood in urine, or new post-menopausal bleeding) need prompt review. Always confirm that energy treatment is appropriate for you now before proceeding (see contraindications below).
How many sessions and follow-up. Clinics often use a short initial series (for example, 2–3 sessions several weeks apart) then a maintenance review at 6–12 months, adjusted to symptoms and goals. If you’re weighing steps, our clinic pages explain what the treatment involves and how we sequence care so you can see where energy devices fit alongside moisturisers, local hormones and rehabilitation.
Who might consider, and who should avoid or delay. People with GSM-predominant symptoms who cannot use or do not wish to use hormones, or who have plateaued after diligent non-hormonal care ± local therapy, sometimes explore energy options. Avoid or delay if you have active infection, an uninvestigated discharge/bleeding change, recent surgery without clearance, a pacemaker/metallic implant in the treatment field (device-specific), or pregnancy. If you have a history of hormone-sensitive cancer, weigh options cautiously with your oncology/menopause teams—energy devices do not replace shared decision-making about local hormones.
Setting expectations. Energy treatments are not a one-size solution; response varies. Some people experience clear benefit; others do better on guideline-led local therapy plus pelvic floor and psychosexual support. Plan a review 6–12 weeks after each step; if progress stalls, reassess diagnosis (e.g., vestibulodynia, lichen sclerosus, BV/UTI, dermatological causes) and technique (is the entrance being treated?).
Clinical Context
Who may suit energy-based care? Those with GSM symptoms (dryness/GSM/atrophy; dyspareunia; urine-on-skin sting) who have tried moisturiser + lubricant + (where acceptable) local oestrogen/DHEA, but remain uncomfortable—especially with vestibular micro-tears or persistent dryness despite good adherence and placement. People averse to local hormones sometimes consider an energy pathway after discussion.
Who should avoid or seek review first? Anyone with red flags: fever, severe pelvic pain, malodorous green/grey discharge, visible haematuria, or any new post-menopausal bleeding. Also pause if you have unhealed surgery, active skin conditions at the site, suspected lichen sclerosus without diagnosis, or unmanaged pelvic floor over-activity (physio first). If deep pain persists despite surface comfort, investigate other pelvic drivers rather than escalating energy intensity.
Next steps. Map symptoms and goals; optimise foundations; confirm diagnosis; then, if still interested, discuss device type, session number, costs, and maintenance. Plan follow-up to step back to the lowest effective maintenance once comfortable.
Evidence-Based Approaches
UK patient guidance on symptoms and self-care: NHS: vaginal dryness. UK guideline framing: NICE NG23 (Menopause) prioritises moisturisers/lubricants and considering low-dose local vaginal oestrogen for GSM when symptoms affect quality of life. Device regulation and safety expectations are overseen by the UK regulator: see the MHRA medical devices pages for vigilance and intended-use principles.
Systematic evidence for energy devices remains evolving and heterogeneous. Cochrane overviews summarise benefits of local oestrogens over placebo for dryness, dyspareunia and pH (useful comparators) and highlight the need for robust trials in alternative modalities; see the Cochrane Library. Peer-reviewed reviews indexed on PubMed discuss GSM pathophysiology (thinner epithelium, raised pH, reduced lactobacilli) and the proposed mechanisms of fractional lasers/RF in vulvo-vaginal tissue.
Applying the evidence: follow a step-wise plan: non-hormonal foundations → add local therapy (oestrogen or DHEA) if needed → consider energy-based options only when guideline-led measures are insufficient or unsuitable, with careful counselling about benefits, limits, cost, and maintenance. Ensure devices are UKCA/CE-marked and operated by trained clinicians with documented consent and aftercare.